In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials.

Autor: Selle K; Locus Biosciences, Inc., Morrisville, North Carolina, USA., Fletcher JR; Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA., Tuson H; Locus Biosciences, Inc., Morrisville, North Carolina, USA., Schmitt DS; Locus Biosciences, Inc., Morrisville, North Carolina, USA., McMillan L; Locus Biosciences, Inc., Morrisville, North Carolina, USA., Vridhambal GS; Locus Biosciences, Inc., Morrisville, North Carolina, USA., Rivera AJ; Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA., Montgomery SA; Department of Pathology and Laboratory Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA., Fortier LC; Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, Canada., Barrangou R; Locus Biosciences, Inc., Morrisville, North Carolina, USA rbarran@ncsu.edu cmtherio@ncsu.edu dave@locus-bio.com.; Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Raleigh, North Carolina, USA., Theriot CM; Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA rbarran@ncsu.edu cmtherio@ncsu.edu dave@locus-bio.com., Ousterout DG; Locus Biosciences, Inc., Morrisville, North Carolina, USA rbarran@ncsu.edu cmtherio@ncsu.edu dave@locus-bio.com.

Publikováno v: MBio [mBio] 2020 Mar 10; Vol. 11 (2). Date of Electronic Publication: 2020 Mar 10.